Maione, S., Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain, Brain, Behavior, and Immunity (2019), doi: https://doi.org/10.1016/j.bbi. 2019.04.006 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 
Abstract
Recent evidence points to the gut microbiota as a regulator of brain and behavior, although it remains to be determined if gut bacteria play a role in chronic pain. The endocannabinoid system is implicated in inflammation and chronic pain processing at both the gut and central nervous system (CNS) levels. In the present study, we used low Vitamin D dietary intake in mice and evaluated possible changes in gut microbiota, pain processing and endocannabinoid system signaling. keywords: Vitamin D deficiency, pain, gut microbiota, endocannabinoids
Introduction
In addition to the typical classification of the central nervous system (CNS) as an immune privileged area, increasing evidence points to the reciprocal communication between the periphery and brain in neurophysiological features, including mood and behavior (Bercik et al., 2011; Johnston et al., 2014) . In particular, the gut microbiota is increasingly considered one of the most important actors in the bidirectional interactions between the intestine and brain, in both physiological and pathological conditions (Scriven et al., 2018) . Several findings indicate that gut microbiota perturbations may produce a local, and subsequently, systemic inflammation, which is believed to trigger neuroinflammation and alterations in brain functioning and behavior (Bercik et al., 2010; Guida et al., 2018; Valles-Colomer et al., 2019) . These findings open the possibility of microbiota-modulating approaches for the treatment of psychiatric diseases and other CNS disorders (Kelly et al., 2017; Misra and Mohanty, 2017) . Studies in germ-free mice and antibiotic-treated animals suggested that the gut microbiota may play a role in pain perception (Luczynski et al., 2017; O'Mahony et al., 2014; Verdu et al., 2006) . However, no studies have explored the role of gut microbiota in chronic pain states, i.e. neuropathic pain. Neuropathic pain is a debilitating pathological condition characterized by abnormal pain perception that is manifested by painful responses to non-painful stimuli (allodynia), which can persist after the leading injury is repaired. This complex process involves plasticity phenomena exerted through modifications in cytokine, chemokine and lipid messenger release, mainly by non-neuronal cells -i.e. microglia and astrocytes -able to induce neuronal sensitization at the spinal cord level. In this context, endocannabinoids and biochemically related mediators, by being important modulators of glia-neuron crosstalk, are strongly implicated in inflammationbased pathological states, including neuropathic pain (Luongo et al., 2010) .
Specifically, the observed dysregulation of endocannabinoid signaling at CB1
and CB2 receptors (CB1R and CB2R), at both the gut (Borrelli and Izzo, 2009; Capasso et al., 2014) and CNS (Giordano et al., 2011; Petrosino et al., 2007) level, have suggested that compounds able to restore a physiological endocannabinoid tone, such as N-palmitoylethanolamine (PEA), may be used for the treatment of inflammation and pain (Guida et al., 2017; Guida et al., 2015b; Luongo et al., 2013) , as well for the correction of some of the central effects associated with microbiota perturbation (Cristiano et al., 2018) . Indeed, pathophysiological mechanisms linking the gut microbiota to the endocannabinoid system in dysbiosis-induced systemic inflammation have been recently proposed (Cani et al., 2016 . Among them, increases in the abundance of A. muciniphila associated with an improved metabolic profile in obese mice have been correlated also with changes in the gut levels of endocannabinoids and endocannabinoid-like mediators Everard et al., 2019) .
In the present study, we used a model of Vitamin D deficiency to induce microbiota perturbation (Jin et al., 2015; Jin et al., 2005) in mice. Indeed, Vitamin D plays a significant role in modulating the immune system in both periphery and CNS. In fact, vitamin D is an important calcium-regulating factor essential for bone homeostasis, metabolism (Plum and DeLuca, 2010) and gut functioning (Sun, 2018) . Altered Vitamin D status have been linked with changes in epithelial barrier functions and microbiome setting in clinical disorders, including irritable bowel syndrome (Jin et al., 2015; Lim et al., 2005; Shang and Sun, 2017; Su et al., 2016) . In addition, Vitamin D, as a neuroactive steroid, exerts neuroimmune-modulating effects resulting in antiinflammatory and neuroprotective actions potentially useful against neurodegenerative and autoimmune diseases (De Abreu et al., 2009) . Indeed, an inverse correlation between Vitamin D levels and painful manifestations has been recently demonstrated to occur in disorders characherised by an overactivated immune system (Akyuz et al., 2017; Herly et al., 2018; Zadro et al., 2017) .
On these bases, we tested the hypothesis that Vitamin D deficiency contributes to pain development, and evaluated whether it does so through the modulation of the endocannabinoid system and the gut microbiome. Therefore, we modified Vitamin D intake in healthy and neuropathic animals. Mice were submitted to behavioral, biochemical and electrophysiological tests to assess whether Vitamin D status may affect behavior and gut microbiota composition, together with the concentrations of central and peripheral endocannabinoids and related N-acylethanolamines. Moreover, since one of such Nacylethanolamines, PEA, is a potent modulator of inflammation and pain, this compound, administered as a micronized formulation previously suggested to exhibit elevated bioavailability (Impellizzeri t al., 2014) , was used as pharmacological tool to investigate the role of endocannabinoid-like mediators in the consequences of Vitamin D deficiency in both the gut and spinal cord.
Material and methods

Animals and treatments
Male C57/bl6 mice (3 weeks) obtained from Envigo Laboratory were housed controlled illumination and environmental conditions for 1 week before the commencement of experiments.
The experimental procedures were approved by the Animal Ethics Committee 
Behavioral testing
Pain
Mechanical allodynia was assessed by using a Simplified Up-Down method (SUDO) (Bonin et al., 2014) , consisting in a modified version of the up-down method introduced by (Chaplan et al., 1994) . Mice were placed on a wire mesh platform and, 1 hour after habituation period, calibrated von Frey filaments (North Coast Medical, Gilroy, CA, USA; ranging from 0.002 to 2.0 g bending force) were applied to the hind paw for 3 to 4 seconds. Five von Frey filament presentations per test were executed and a lack of response to a filament dictates that the next higher filament is used in the following stimulation, while a positive response dictates the use of the next lower filament. The PWT is assumed to exist in the vicinity of a stimulus level where the animal first changes its response pattern: a negative response followed by a positive response or vice versa. The PWT estimation is recorded as the response to the fifth stimulus.
Mice were tested at day 0 (baseline), at 6 weeks (diet timing) before SNI and, at day 7 post SNI when the allodynia was established and after various pharmacological interventions every 10 min for 60 min. The mean of paw withdrawal thresholds (g) was reported for each experimental group.
Tail flick test. Mice were gentle placed on the tail flick unit (Ugo Basile, Italy) and the thermal stimulus was elicited by a radiant heat source focused on the mice tail approximately 1 to 3 cm from the tip. Tail-flicks were elicited before and after injecting drugs every 10 min for 60 min. The mean (sec) of paw withdrawal thresholds was reported for each experimental group.
Neuropathy induction
The spared nerve injury. Mononeuropathy was induced according to the method of Decosterd and Woolf Decosterd and Woolf, 2000) . Mice were anesthetized by intraperitoneal injection of ketamine xylazine (60 mg/kg + 10 mg/kg). The sciatic nerve was exposed at the level of its trifurcation into sural, tibial, and common peroneal nerves. The tibial and common peroneal nerves were ligated tightly with 7.0 silk threads and then transected just distal to the ligation, leaving the sural nerve intact. Sham mice were anesthetized, and the sciatic nerve was exposed at the same level, but it was not transected.
Western blotting analysis
Each animal, previously anesthetized, was decapitated and spinal cord 
Extracellular Recordings of Nociceptive Specific Neurons (NS)
For in vivo single unit extracellular recording, mice were initially anesthetized with Avertin (1.25%). After tracheal cannulation, a catheter was placed into the right external jugular vein to allow continuous infusion of propofol (5-10 mg/kg/h, i.v.). Spinal cord segments L4-L6 were exposed medially by laminectomy, near the dorsal root entry zone, up to a depth of 1 mm (McGaraughty et al., 2010 ). An elliptical rubber ring (about 3 × 5mm) was Haer & Co., ME, USA) was used to record single unit extracellular activity of dorsal horn NS neurons. NS neurons were defined as those neurons that respond only to high-intensity (noxious) stimulation (Telleria-Diaz et al., 2010) . To confirm NS response patterns, each neuron was characterized while applying a mechanical stimulation to the ipsilateral hind paw using a von Frey filament with 97.8 mN bending force (noxious stimulation) for 2s until it buckled slightly (Boccella et al., 2015; Simone et al., 2008) . Only neurons that responded specifically to the noxious hind paw stimulation, without responding to stimulation of the surrounding tissue, were included. The recorded signals were amplified and displayed on a digital storage oscilloscope to ensure that the unit under study was unambiguously discriminated throughout the experiment. Signals were also fed into a window discriminator, whose output was processed by an interface CED 1401 (Cambridge Electronic Design Ltd., UK) connected to a Pentium III PC. Spike2 software (CED, version 4) was used to create peristimulus rate histograms online and to store and analyze digital records of single unit activity offline. Configuration, shape, and height of the recorded action potentials were monitored and recorded continuously using a window discriminator and Spike2 software for online and offline analysis. This study only included neurons whose spike configuration remained constant and could be clearly discriminated from activity in the background throughout the experiment, indicating that the activity from one neuron only and from the same neuron was measured. The neuronal activity was expressed as spikes/sec (Hz). The total number of NS neurons recorded per electrode descent (track) was also calculated, since the number of neurons recorded is a valid, indirect index of the percentage of neurons that are active during in vivo electrophysiological recordings (Bambico et al., 2007) . At the end of the experiment, each animal was killed with a lethal dose of urethane.
Endocannabinoids measurement
Spinal cord, jejunum, ileum, colon and duodenum were homogenized with 
DNA extraction and 16S rRNA amplicon sequencing
Total DNA from fecal samples was used for DNA extraction, by using the DNeasy PowerSoil kit (Qiagen). V3-V4 region of the 16S rRNA gene was amplified by using primer S-D-Bact-0341 and S-D-Bact-0785 as previously described (Berni Canani et al., 2017) . PCR products were purified with the Agencourt AMPure XP beads and quantified using a Plate Reader AF2200.
Amplicon multiplexing, pooling and sequencing was carried out following the Illumina 16S Metagenomic Sequencing Library Preparation protocol, on a MiSeq platform and using the MiSeq Reagent kit v3, leading to 2x300 bp, paired-end reads.
Statistical analysis
Data were represented as mean ± S.E.M. The behavioural data were analysed using one-way ANOVA, followed by One-way ANOVA, post-hoc Tukey's. The unpaired T-test with Mann Whitney test for intra-groups analysis (N = 10-12).
Electrophysiological data were analysed using one-way ANOVA, followed by
Holm-Sidack post hoc comparisons or t-test (N = 6-8). Biomolecular data were expressed as mean ± SD and were analysed by one-way ANOVA, post-hoc Tukey's (N = 5-6).
Microbiota data analysis
Demultiplexed, forward and reverse reads were joined by using FLASH (Magoc and Salzberg, 2011). Joined reads were quality trimmed (Phred score <20) and short reads (<250 bp) were discarded by using Prinseq (Schmieder and Edwards, 2011). High quality reads were then imported in QIIME 1.9
(Caporaso et al., 2010). Operational taxonomic units (OTUs) were picked through a de novo approach and uclust method and taxonomic assignment was obtained by using the Ribosomal Database Project (RDP) classifier and the Greengenes (McDonald et al., 2012) database, following a pipeline previously reported (Berni Canani et al., 2017) . In order to avoid biases due to the different sequencing depth, OTU tables were rarefied to the lowest number of sequences per sample. Statistical analyses and visualization were carried out in R environment (https://www.r-project.org). Alpha-diversity analysis was carried out in QIIME on rarefied OTU tables. Kruskal-Wallis and pairwise
Wilcoxon tests were used in order to determine significant differences in alpha diversity parameters or in specific taxa abundance. Correction of p-values for multiple testing was performed when necessary.
The 16S rRNA gene sequences produced in this study are available at the Sequence Read Archive (SRA) of the National Center for Biotechnology Information under accession number SRP170185.
Results
Vitamin D deficiency induces allodynia associated with spinal neuronal sensitization
After weaning, mice were fed a diet with normal or low vitamin D concentrations for 6 weeks. No differences in food intake or corresponding body weights were observed between groups throughout the experimentation (not shown). NS in Vitamin D normal mice (Fig. 1 H) . animals. Circulating 25OHD levels were 60.9 ng/ml ± 0.9 in control mice, while they were significantly (P<0.0001) reduced to 12.23 ng/ml ± 0.2 in low Vitamin D group (Fig. 2 B) . Interestingly, SNI did not affect the circulating 25OHD levels (Fig. 2 B) , however it significantly increased spinal VDR expression, in both Vitamin D normal and deficient mice (5.58±0.15 vs 6.16±0.055, F3,12=28.39, p<0.0001) (Fig. 2 C) . Notably, spinal VDR expression levels resulted significantly augmented also in sham animals exposed to the low Vitamin D diet, as compared with sham animals fed with control diet (1±0.028 vs 1.91±0.032, F3,12=28.39, p<0.0001) (Fig. 2 C) .
Spared nerve injury increases spinal VDR expression without affecting serum vitamin D levels
CB1R and CB2R involvement in Vitamin D deficiency-induced allodynia
Compared with controls, Vitamin D deficient animals showed reduced spinal CB1R expression levels, as revealed by western blotting analysis (0.43±0.042 vs 1±0.062, F3,12=41.76, p<0.0001) (Fig. 3 A) . The intraperitoneal administration of synthetic CB1R agonist ACEA (10 mg/kg i.p.) did not change the mechanical threshold in all experimental groups (Fig. 3 B) (Fig. 3 D) .
Interestingly, Vitamin D deficient animals showed increased CB2R expression levels as compared with control animals (3.99±0.02 vs 1.00±0.02, F3,4=7962, p<0.0001) (Fig. 3 E) (Fig. 3 J) . These data suggest that CB2R might become dysfunctional (i.e. uncoupled to its signaling pathway) during vitamin D deficiency in SNI mice.
PEA reduces the allodynia and neuronal sensitization in Vitamin D deficiency
Having established that both CB1R and CB2R agonists are ineffective at correcting the allodynia induced by vitamin D deficiency, we next evaluated the effect of exogenous PEA, and endocannabinoid-like molecule which does not directly activate the two cannabinoid receptors and acts instead via several different molecular targets (Petrosino and Di Marzo, 2017) . The dose of PEA was chosen according to our previously published studies (Guida et al., 2017; Guida et al., 2015a; Luongo et al., 2013) .
Whereas a single injection of PEA (10 revealed by two-way ANOVA followed by Bonferroni post-hoc test (Fig. 4 C-E).
No differences in NS activity in Vitamin D normal mice were observed after PEA injection, as compared to vehicle-treated animals (p>0.05) (Fig. 4 
B, C-E).
Remarkably, Vitamin D deficient mice showed increased (~20-fold) expression levels of PPAR-α at the spinal cord level, compared with normal vitamin D animals (23.36±0.18 vs 1±0.11, F3,12=3167, p<0.0001) (Fig. 4 F) (Fig. 4 G) , although we did not perform any experiments with the compound in the presence of a PPAR- antagonist to confirm or discard this hypothesis. 
Changes in endocannabinoid and endocannabinoid-like mediator levels in the spinal cord
Changes in endocannabinoid and endocannabinoid-like mediator levels in the gut
The levels of AEA, 2-AG, PEA, OEA, DHEA and EPEA in the mouse jejunum, ileum, colon and duodenum are shown ( Fig. 6 A and B ; supp. Fig. 3 ). In all four tissues, PEA treatment was found to lead to the expected strong and significant increase in PEA levels only in vitamin D normal mice, and much less so in vitamin D deficient mice, indicating that the absence of vitamin D in the diet modulates the absorption or metabolism of this compound in both the small and large intestine in a manner to reduce its intestinal levels.
Interestingly, the co-occurrence of neuropathy reduced the bioavailability of PEA in the ileum and duodenum, but not in the colon and jejunum (Fig. 6 A and B; supp. Fig. 3 ).
The levels of other N-acylethanolamines and 2-AG in the four intestinal tissues did not significantly change with most of the treatments. Notable exceptions to this rule were: 1) the colon, where vitamin D deficiency per se reduced 2-AG levels ( Fig. 6 A) , and PEA elevated AEA, OEA and DHEA levels only in vitamin D normal SNI mice ( Fig. 6 A) ; and 2) the duodenum, where PEA elevated DHEA levels in both vitamin D normal and deficient non-SNI mice (Fig. 6 B) . These findings may suggest, respectively, that: 1) vitamin D deficiency may also be accompanied by increased pain and inflammation due to reduced endocannabinoid (i.e. 2-AG) signaling at intestinal CB1R and CB2R, and its subsequent amelioration by PEA, and 2) PEA may produce anti-inflammatory effects in the small intestine in both vitamin D normal and deprived mice by elevating DHEA levels. This hypothesis will require ad hoc studies on the effects of vitamin D deficiency, with or without PEA administration, in models of visceral pain and intestinal inflammation.
In view of the previously reported effects of endocannabinoids and Nacylethanolamines on the gut microbiota (Cristiano et al., 2018) , the findings in the small intestine overall may also suggest that vitamin D deficiency, on the one hand, and PEA administration, on the other hand, might be accompanied by changes in fecal microbiota composition, which reflects colonic and, to a smaller extent, small intestinal, microbiota composition.
Changes in gut microbiota
Gut microbiota composition and diversity was strongly affected by the decreased intake of vitamin D, while animals following a standard diet clustered together regardless of the neuropathy or PEA treatment (Fig. 7 A) .
VitD deficient mice showed a lower microbial diversity compared to control mice ( Fig. 7 B, p<0 .05).
In healthy, untreated mice the vitD deficient diet was linked to an increase in Firmicutes and a decrease in Verrucomicrobia and Bacteroidetes (p<0.05).
Moreover, the treatment with PEA in animals following a diet deficient in vitamin D led to higher levels of Akkermansia, Eubacterium and Enterobacteriaceae (Fig. 8) .
Discussion
The aim of this study was to explore the role of the microbiota-gut-CNS axis in (Wu and Sun, 2011) , and that its increased expression is not accompanied by its coupling to anti-allodynic pathways.
Remarkably, the injection of a multi-target endocannabinoid-like Nacylethanolamine, i.e. PEA, reverted chronic pain and neuronal excitability, together with spinal endocannabinoid levels dysregulation (AEA and DHEA).
The analgesic effects of PEA have been previously demonstrated in different animal models associated with chronic pain (Guida et al., 2017; Guida et al., 2015b; Impellizzeri et al., 2014; Luongo et al., 2013) . However, our data suggest novel therapeutic properties of PEA, which may be helpful to compensate, or amplify the endogenous protection mechanisms deployed in vitamin D deficiency-associated dysfunctions. Although investigating PEA mechanism of action was not among the aims of the present study, we found that PPAR-α, known to be responsible for several pharmacological properties of PEA (Citraro et al., 2013; Di Cesare Mannelli et al., 2013; Scuderi et al., 2012; Serena et al., 2018) , was increased in the absence of Vitamin D. Indeed, the interaction between VDR and PPAR-α, both requiring heterodimerization with retinoic x receptor (RXR) to exert their activity through response element binding, has been previously suggested (Sertznig and Reichrath, 2011; Zella et al., 2006) . However, we cannot exclude that PPAR-α over-expression could be also due to possible metabolic alterations in lipid metabolism and glucose homeostasis commonly associated with Vitamin D deficiency, but normally observed in other tissues and organs (Nakamichi et al., 2017; Sharma and Staels, 2006; Takahashi et al., 2017) .
With regard to PEA-induced reduction of spinal AEA and DEHA levels observed after PEA injection in vitamin D deficient mice, it is reasonable to hypothesize that this effect was not responsible for pain amelioration, but instead represents an adaptive mechanism to PEA-induced analgesia, possibly exerted via one or more of the different targets of this mediator, such PPAR- or the orphan G-protein-coupled receptor GPR55 (Raso et al., 2014) .
In the gut, vitamin D deficiency produced significant decreases of 2-AG levels in the colon, confirming the dual role of the endocannabinoid system in gut pathophysiology (Cani et al., 2016) . Endogenous PEA levels were not affected by diet, but they resulted increased, as expected, after injection of exogenous PEA. This effect was more evident in control (colon, jejunum and duodenum)
than Vitamin D deficient mice, suggesting possible changes in drug bioavailability/distribution or anatomical changes induced by the pathological situation. Interestingly, PEA strongly increased DHEA levels in both vitamin D normal and deprived mice in the duodenum, suggesting a possible link between PEA protective effects in the small intestine and elevated DHEA levels.
This hypothesis should be investigated in future studies, and is supported by the previous finding that DHEA and its metabolites exhibit anti-inflammatory and organ-protective properties (Yang et al., 2011) .
The correlation between vitamin D status and neuropathic pain was investigated by applying the SNI to Vitamin D deficient mice. This is a wellestablished model of neuropathic pain associated with neuronal firing changes at the spinal and supraspinal levels, as well as with neuropsychiatric disorders (Guida et al., 2015a; Sagheddu et al., 2015) . Interestingly, SNI mice showed reduced spinal AEA and DHEA levels. These results are in agreement with previous findings (Bishay et al., 2013; Petrosino et al., 2007) and, based on the neuroprotective, antinociceptive and antiinflammatory properties of these bioactive lipids (Yang et al., 2011), may suggest that this dysregulation participates in SNI-induced allodynia, inflammation and neuronal damage. As expected, spinal PEA levels resulted increased after the injection of exogenous PEA, although such an increase was strong and statistically significant only in SNI mice, suggesting an increased permeability of the blood spinal cord barrier following this neuropathic condition (Guida et al., 2015b) . Interestingly, the effect of PEA on spinal AEA, 2-AG and DHEA levels described above for vitamin D deficient mice was not observed in SNI mice, with or without vitamin D deficiency. This finding is counterintuitive given: 1) the well-known "entourage effect" of PEA on AEA and 2-AG levels (Re et al., 2007) , 2) the analgesic actions of AEA and 2-AG and the anti-inflammatory action of DHEA (Yang et al., 2011) , and 3) the fact that PEA ameliorated allodynia. If, as mentioned above, the negative effects of PEA on the spinal cord levels of these mediators may be explained as a possible adaptive mechanism aimed at reducing the effects of endogenous analgesic mediators in response to an exogenous and per se analgesic compound, the fact that these negative effects are missing in the corresponding SNI mice may suggest, instead, that the analgesic effect of PEA in these neuropathic mice are partly due also to the lack of inhibition on endogenous analgesic/antiinflammatory mediator signaling. All together, these data suggest the SNIinduced changes in spinal cord endocannabinoid and N-acylethanolamine signaling are not affected by Vitamin D deficiency.
At the gut level, we found that the co-occurrence of neuropathy reduced the bioavailability/distribution of PEA, specifically in the ileum and duodenum, but not in the colon and jejunum. Since PEA was equally effective at reducing allodynia in both SNI mice and vitamin D deficient mice, it can be surmised that the levels of this compound in the small and large intestine do not determine its analgesic efficacy. Moreover, in the colon PEA treatment elevated AEA, OEA and DHEA levels only in vitamin D normal SNI mice, suggesting the contribution of these bioactive lipids in the protective effects of PEA in the gut (Capasso et al., 2014; Esposito et al., 2014) .
In the gut, altered vitamin D status may influence commensal bacterial composition and viceversa (Luthold et al., 2017 ). In our model the absence of vitamin D generated a marked dysbiosis, with a loss of bacterial diversity. We also demonstrated that SNI does not impact on microbiota composition.
However, PEA treatment was associated with the production of higher levels of some specific gut bacterial species, restrictively in the low Vitamin D condition (with or without SNI), including A. muciniphila. This latter species, together with other bacteria, resulted instead decreased by low vitamin D diet.
Associations between Eubacterium and Enteronbacteriaceae with PEA or other neuroactive compounds have not been documented. Given the protective effects of A. muciniphila in several (not uniquely metabolic) functions (Dao et al., 2016) , the finding that it can increase upon PEA treatment against pain and spinal cord hyperexcitability, supports a possible involvement of the gut microbiota in pain (Luczynski et al., 2017; O'Mahony et al., 2014; Verdu et al., 2006) . Moreover, beneficial endocannabinoidome mediators such as PEA may contribute in correcting the effects of dysbiosis (Cristiano et al., 2018) . A.
muciniphila administration induces an increase in intestinal levels of endocannabinoid-related metabolites in high fat diet-fed mice, with protective effects on gut-barrier integrity and inflammation (Cani, 2014) . Additionally, deletion of a N-acylethanolamine biosynthetic enzyme from the adipose tissue was found to be accompanied by systemic inflammation only when resulting in the decrease of the endogenous levels of non-endocannabinoid Nacylethanolamines, including PEA (Geurts et al., 2015) . Thus, the present findings of a correlation between A. muciniphila abundance and the analgesic effects mediated by PEA support the existence of a link between commensal bacteria and endocannabinoids and, particularly, their related mediators in inflammation and host metabolism Muccioli et al., 2010) , at least in cases of in vitamin D deficiency. Further analysis will be necessary to identify possible biomolecules or bacterial products released from the gut into the systemic circulation, which may exert a role in the pathophysiology of pain. Moreover, given the presence of high levels of VDR in the brain (hippocampus, hypothalamus, thalamus, cortex, and substantia nigra) (Moretti et al., 2018) , we cannot exclude that vitamin D deficiency may directly affect neuronal well-functioning in specific brain regions involved in pain processing.
Conclusions
In conclusion, our results suggest that Vitamin D deficiency, and associated changes in spinal cord sensory neuron activity, possibly together with altered gut bacterial composition, may cause pain behavior via molecular mechanisms involving at least in part the endocannabinoid and N-acylethanolamine signaling systems. We also demonstrate that the neuropathic pain state induced in the present study, instead, does not affect microbiota composition.
This latter finding seems to reinforce the hypothesis that, of the vitamin D deficiency-induced effects observed here, it is the dysbiosis that may concur to increase pain rather than the contrary. The fact that exogenous PEA: 1) modifies gut microbiota composition, and 2) produces certain changes in the spinal levels of endocannabinoids and related molecules, only during vitamin D deficiency-induced, and not in SNI-induced, pain also suggests a specific role of these two complex systems in the consequences of this defective dietary condition. Indeed, we have pointed out the potential relationship between particular gut microbial relative abundances and endocannabinoid and endocannabinoid-like molecules in the course of vitamin D deficiency-induced pain, as well as in its pharmacological treatment with one of such molecules.
We suggest novel therapeutic properties for PEA, which may be advantageous to counteract vitamin D deficiency-associated dysfunctions, possibly also via its effects on the gut microbiome and endocannabinoidome. Vitamin D deficiency is associated with chronic pain development and electrophysiological and biochemical changes at spinal cord level.
The N-acylethanolamine, palmitoylethanolamide counteracts most of these behavioral and biochemical changes, whilst affecting gut microbiota composition.
